Wirksamkeit und Sicherheit von Tacalcitol-Salbe in der Langzeitanwendung bei chronischer Plaque Psoriasis. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis

Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis

British Journal of Dermatology ◽

10.1046/j.1365-2133.2002.04567.x ◽

2002 ◽

Vol 146 (3) ◽

pp. 414-422 ◽

Cited By ~ 45

Author(s):

P.C.M. Van De Kerkhof ◽

J. Berth-Jones ◽

C.E.M. Griffiths ◽

P.V. Harrison ◽

H. Honigsmann ◽

...

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study

10.1016/j.jaad.2015.03.040 ◽

2015 ◽

Vol 73 (2) ◽

pp. 331-333.e1 ◽

Cited By ~ 13

Author(s):

Sunil Dogra ◽

Krupashankar D.S. ◽

Leelavathy Budamakuntla ◽

C.R. Srinivas ◽

Uday Khopkar ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

British Journal of Dermatology ◽

10.1111/bjd.18029 ◽

2019 ◽

Vol 181 (6) ◽

pp. 1177-1189 ◽

Cited By ~ 5

Author(s):

D. Thaçi ◽

K. Papp ◽

D. Marcoux ◽

L. Weibel ◽

A. Pinter ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Term Efficacy ◽

Paediatric Patients ◽

Phase Iii Study

Short- and long-term efficacy and safety of adalimumab in a pivotal phase III study in adult patients with moderate to severe chronic plaque psoriasis

10.1016/j.jaad.2006.10.073 ◽

2007 ◽

Vol 56 (2) ◽

pp. AB5

Keyword(s):

Plaque Psoriasis ◽

Adult Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Pivotal Phase ◽

Term Efficacy ◽

Phase Iii Study ◽

Short And Long Term

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

British Journal of Dermatology ◽

10.1111/bjd.20595 ◽

2021 ◽

Author(s):

K.A. Papp ◽

M.G. Lebwohl ◽

L. Puig ◽

M. Ohtsuki ◽

S. Beissert ◽

...

Keyword(s):

Plaque Psoriasis ◽

Interim Analysis ◽

Efficacy And Safety ◽

Open Label ◽

Severe Plaque Psoriasis ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Long-term efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis sustained for three years: Results of a randomized controlled phase 3 study (UNCOVER-3)

10.1016/j.jaad.2018.05.732 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB180

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Randomized Controlled ◽

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

10.1016/j.jaad.2016.01.013 ◽

2016 ◽

Vol 74 (5) ◽

pp. 841-850 ◽

Cited By ~ 78

Author(s):

Kim A. Papp ◽

James G. Krueger ◽

Steven R. Feldman ◽

Richard G. Langley ◽

Diamant Thaci ◽

...

Keyword(s):

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Janus Kinase Inhibitor ◽

Phase Iii Studies

Long-term efficacy of up to 15 months’ efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis

Dermatologic Therapy ◽

10.1111/j.1529-8019.2008.00235.x ◽

2008 ◽

Vol 21 ◽

pp. S6-S14 ◽

Cited By ~ 5

Author(s):

Darryl P. Toth ◽

Kim Papp ◽

David Gratton

Keyword(s):

Plaque Psoriasis ◽

Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study

The Journal of Dermatology ◽

10.1111/1346-8138.14761 ◽

2019 ◽

Vol 46 (3) ◽

pp. 186-192 ◽

Cited By ~ 6

Author(s):

Yukari Okubo ◽

Mamitaro Ohtsuki ◽

Akimichi Morita ◽

Masako Yamaguchi ◽

Tomohiro Shima ◽

...

Keyword(s):

Plaque Psoriasis ◽

Japanese Patients ◽

Extension Study ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)

The Journal of Dermatology ◽

10.1111/1346-8138.15763 ◽

2021 ◽

Author(s):

Shinichi Imafuku ◽

Hidemi Nakagawa ◽

Atsuyuki Igarashi ◽

Akimichi Morita ◽

Yukari Okubo ◽

...

Keyword(s):

Plaque Psoriasis ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽